+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are studying nerandomilast as a potential treatment for adults with systemic sclerosis SSc, a condition that causes skin thickening and affects internal organs. This phase 3 trial aims to evaluate whether nerandomilast improves symptoms and slows disease progression in people with limited or diffuse cutaneous SSc who have had disease onset within 7 years of their first non-Raynauds symptom. The study is sponsored by Boehringer Ingelheim and compares nerandomilast to a placebo in a double-blind, randomized design. Participants are randomly assigned to one of two groups one group takes nerandomilast tablets and the other takes placebo tablets. Both types of tablets are film-coated and look the same. Participants take these tablets twice daily. The study lasts from 1 to about 4 years, during which participants attend regular visits and receive phone calls from study staff. The trial includes adults with active disease who may be untreated or on stable immunosuppressive treatments. During the study, participants undergo repeated assessments including blood tests and evaluations of skin thickening, lung function, and overall health. Doctors also monitor internal organs and check for any side effects or safety concerns related to the treatment. The main outcome measured is the time until disease progression or death over up to 4 years. Other outcomes include changes in skin score, lung function, and quality of life. Safety and tolerability are closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
248 locations
P

Actively Recruiting

This research aims to evaluate the effectiveness of luspatercept in adults with very low, low, or intermediate risk myelodysplastic syndromes MDS who have anemia but do not require blood transfusions and have not been treated with erythropoiesis-stimulating agents ESA. It focuses on patients who are transfusion-independent and have symptomatic anemia, studying the response to treatment in this specific group. All participants receive luspatercept administered as a subcutaneous injection at a dose of 1.75 mg per kg of body weight every 21 days. This treatment continues for 24 weeks initially, and for those who respond by week 25, therapy may extend for up to 1.5 years or until loss of response. This is a single-arm, open-label phase II study without a placebo group. Participants will have assessments at regular intervals, including blood tests and bone marrow sampling, to monitor blood cell counts and treatment response. The main outcome is erythroid response measured after eight treatment cycles each cycle is 21 days. Secondary outcomes include the duration of response, time to response, neutrophil and platelet responses, safety monitoring for adverse effects, and quality of life evaluations using validated questionnaires. The study lasts up to 48 months, including long-term follow-up.

Age: 18Years +All GendersPhase 2
22 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Cemiplimab as a first-line treatment for patients with locally advanced basal cell carcinoma BCC who have not previously received hedgehog inhibitor therapy. This phase II, open-label, single-arm trial aims to measure the objective response rate after six months of treatment in this patient group. Patients with advanced BCC who cannot undergo surgery or radiotherapy are included to explore new treatment options. Participants will receive Cemiplimab intravenously at a dose of 350 mg on day 1 of every 21-day cycle for up to 12 months or a maximum of 17 cycles. Treatment may stop earlier if intolerable side effects or disease progression occurs. Tumor samples will be collected for research to identify potential biomarkers that may relate to the drugs effectiveness. The study also includes follow-up visits every 12 weeks to monitor response and safety until death or for up to 12 months after the last dose. Throughout the study, patients will have regular assessments including tumor response evaluations every 12 weeks during treatment and follow-up. Researchers will monitor safety by tracking adverse events and laboratory parameters. The main outcome measured is the objective response rate at six months, with additional measures such as progression-free survival and overall survival tracked for up to 42 months. Participants are followed closely to understand both the benefits and risks of Cemiplimab in this setting.

Age: 18Years +All GendersPhase 2
7 locations
I

Actively Recruiting

Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.

All AgesAll Genders
317 locations
O

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a subcutaneous treatment using one cycle of cladribine for patients with hairy cell leukemia who need treatment. This study focuses on patients who are either untreated or have been previously treated only with alpha-interferon. The goal is to determine the rate of complete remission and to assess whether a second cycle of treatment benefits those with a non-optimal response, defined as detectable residual disease or partial remission four months after the initial treatment. Participants receive cladribine at a dose of 0.14 mgkg body weight administered subcutaneously as a bolus injection once daily for five consecutive days. After four months, remission status is evaluated. Patients showing non-optimal response may be considered for a second treatment cycle. This phase 23 trial is designed to optimize therapy for hairy cell leukemia by closely monitoring treatment response and toxicity. During the study, participants undergo evaluations including disease status assessment through bone marrow and blood tests, with a focus on remission rates four months post-treatment. Researchers track complete remission rates and monitor for residual disease. Safety is also monitored by assessing potential toxicities. Participants general health status and other laboratory tests are reviewed to ensure eligibility and ongoing suitability for treatment throughout the study period, which spans several months with follow-up assessments.

Age: 18Years - 90YearsAll GendersPhase 2Phase 3
76 locations